Washington, DC, United States of America

Eda Gjika

This inventor holds 1 USPTO granted patent. Top assignee: The George Washington University. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eda Gjika: Innovator in Cancer Treatment Technology

Introduction

Eda Gjika is a prominent inventor based in Washington, DC, known for her groundbreaking work in cancer treatment technology. She has made significant contributions to the field of medical innovation, particularly in the area of sensitizing cancer cells to chemical treatments.

Latest Patents

Eda Gjika holds a patent for a method and system of sensitizing cancer cells to chemical treatment by plasma-based activation. This innovative approach involves using a cold atmospheric plasma jet to treat diseased tissues, such as areas with cancerous cells. The process includes ionizing a gas, such as helium, to create an initial plasma jet that is directed toward the affected area for a sufficient duration, typically around 10 seconds. This treatment sensitizes the cancer cells, enhancing the effectiveness of subsequent reactive treatments, such as H2O2 or TMZ.

Career Highlights

Eda Gjika is affiliated with Washington University, where she continues to advance her research and development in cancer treatment technologies. Her work is characterized by a commitment to improving patient outcomes through innovative medical solutions.

Collaborations

Eda collaborates with esteemed colleagues, including Dayun Yan and Michael Keidar, who contribute to her research efforts and the development of her patented technologies.

Conclusion

Eda Gjika's contributions to cancer treatment through her innovative patent demonstrate her dedication to advancing medical science. Her work not only highlights her expertise but also reflects the potential for new technologies to improve treatment outcomes for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…